ijms-logo

Journal Browser

Journal Browser

Molecular Research on Kidney Disease/Renal Dysfunction

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1144

Special Issue Editor


E-Mail Website
Guest Editor
Division of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto, Saitama 364-8501, Japan
Interests: erythropoietin; hypoxia; renal anemia; acid-base balance; hypertension
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Kidney plays a main role for the regulation of body fluid homeostasis including the adaptation to hypoxia and anemia. Diabetic nephropathy is the most common causative disease of chronic kidney disease (CKD) and chronic renal failure (CRF). Erythropoiesis-stimulating Agents (ESAs) and hypoxia-inducible factor-prolyl hydroxylase (HIF-PHD) inhibitors largely changed the treatment of renal anemia. Recently sodium-glucose co-transporter 2 (SGLT2) inhibitors have been known to improve renal anemia and renal dysfunction. Our special issue would like to focus on the developments and current status of the diagnosis and treatments of various renal diseases.

Dr. Hiroshi Nonoguchi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • kidney disease/renal dysfunction
  • hypoxia-inducible factor-prolyl hydroxylase (HIF-PHD) inhibitors
  • renal anemia
  • chronic renal faikure

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1203 KiB  
Article
Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia
by Yoshitaka Shimada, Yuichiro Izumi, Yukiko Yasuoka, Tomomi Oshima, Yasushi Nagaba, Masayoshi Nanami, Jeff M. Sands, Noriko Takahashi, Katsumasa Kawahara and Hiroshi Nonoguchi
Int. J. Mol. Sci. 2024, 25(17), 9468; https://doi.org/10.3390/ijms25179468 - 30 Aug 2024
Viewed by 934
Abstract
Many large-scale studies revealed that exogenous erythropoietin, erythropoiesis-stimulating agents, have no renoprotective effects. We reported the renoprotective effects of endogenous erythropoietin production on renal function in ischemic reperfusion injury (IRI) of the kidney using the prolyl hydroxylase domain (PHD) inhibitor, Roxadustat. The purpose [...] Read more.
Many large-scale studies revealed that exogenous erythropoietin, erythropoiesis-stimulating agents, have no renoprotective effects. We reported the renoprotective effects of endogenous erythropoietin production on renal function in ischemic reperfusion injury (IRI) of the kidney using the prolyl hydroxylase domain (PHD) inhibitor, Roxadustat. The purpose of this study was to investigate the effects of daprodustat on the progression of chronic renal failure. We retrospectively investigated the effects of daprodustat on the progression of chronic renal failure and renal anemia in patients with stages 3a-5 chronic kidney diseases (estimated glomerular filtration rate, eGFR < 60 mL/min/1.73 m2). The results show that daprodustat largely slowed the reduction in eGFR. The recovery of renal function was observed in some patients. Daprodustat is useful not only for renal anemia but also for the preservation of renal function. The renoprotective effect of daprodustat was small in patients with serum creatinine larger than 3–4 mg/dL because of low residual renal function. The appearance of renal anemia would be a sign of the time to start using daprodustat. Full article
(This article belongs to the Special Issue Molecular Research on Kidney Disease/Renal Dysfunction)
Show Figures

Figure 1

Back to TopTop